Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893354345> ?p ?o ?g. }
- W2893354345 endingPage "619" @default.
- W2893354345 startingPage "609" @default.
- W2893354345 abstract "Resistance to HER2-targeted therapy with trastuzumab still remains a major challenge in HER2-amplified tumors. Here we investigated the potential role of MEL-18, a polycomb group gene, as a novel prognostic marker for trastuzumab resistance in HER2-positive (HER2+) breast cancer.The genetic alteration of MEL-18 and its clinical relevance were examined in multiple breast cancer cohorts including METABRIC (n = 1,980), TCGA (n = 825), and our clinical specimens (n = 213, trastuzumab-treated HER2+ cases). MEL-18 amplification was validated by fluorescence in situ hybridization (FISH) analysis. The MEL-18 effect on trastuzumab response was confirmed by in vitro cell viability assays and an in vivo xenograft experiment (n = 7 per group). Gene expression microarray and receptor tyrosine kinase array were performed to identify the trastuzumab resistance mechanism by MEL-18 loss. All statistical tests were two-sided.MEL-18 was exclusively amplified in approximately 30-50% of HER2+ breast tumors and was associated with a favorable clinical outcome (disease-free survival: P = .02 in HER2+ cases, METABRIC; P = .04 in patients receiving trastuzumab). In MEL-18-amplified HER2+ breast cancer, MEL-18 depletion induced trastuzumab resistance by increasing ADAM sheddase-mediated ErbB ligand production and receptor heterodimerization. MEL-18 epigenetically silenced ADAM10/17 expression in cooperation with polycomb-repressive complex (PRC) 1 and PRC2. Combination treatment with an ADAM10/17 inhibitor and trastuzumab could overcome MEL-18 loss-mediated trastuzumab resistance in vivo (BT474/shMEL-18 xenograft: trastuzumab, mean [SD] tumor volume = 406.1 [50.1] mm3, vs trastuzumab + GW280264 30 mg/kg, mean [SD] tumor volume = 68.4 [15.6] mm3, P < .001). Consistently, trastuzumab-treated patients harboring concomitant MEL-18 amplification and low ADAM17 expression showed prolonged relapse-free survival (P = .02 in our cohort, n = 213).MEL-18 serves to prevent ligand-dependent ErbB heterodimerization and trastuzumab resistance, suggesting MEL-18 amplification as a novel biomarker for HER2+ breast cancer." @default.
- W2893354345 created "2018-10-05" @default.
- W2893354345 creator A5001681907 @default.
- W2893354345 creator A5024020131 @default.
- W2893354345 creator A5026587236 @default.
- W2893354345 creator A5026689196 @default.
- W2893354345 creator A5033320671 @default.
- W2893354345 creator A5034859314 @default.
- W2893354345 creator A5037860926 @default.
- W2893354345 creator A5061910936 @default.
- W2893354345 creator A5068859596 @default.
- W2893354345 creator A5068972361 @default.
- W2893354345 creator A5073578496 @default.
- W2893354345 creator A5074604844 @default.
- W2893354345 creator A5075938435 @default.
- W2893354345 creator A5090134634 @default.
- W2893354345 date "2018-09-27" @default.
- W2893354345 modified "2023-10-06" @default.
- W2893354345 title "Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer" @default.
- W2893354345 cites W1506037014 @default.
- W2893354345 cites W1536466400 @default.
- W2893354345 cites W1734411634 @default.
- W2893354345 cites W1789716240 @default.
- W2893354345 cites W1828440160 @default.
- W2893354345 cites W1890687016 @default.
- W2893354345 cites W1988142400 @default.
- W2893354345 cites W1993804787 @default.
- W2893354345 cites W1995652309 @default.
- W2893354345 cites W1996947994 @default.
- W2893354345 cites W2005895632 @default.
- W2893354345 cites W2007531307 @default.
- W2893354345 cites W2015132841 @default.
- W2893354345 cites W2016910890 @default.
- W2893354345 cites W2018692167 @default.
- W2893354345 cites W2024099613 @default.
- W2893354345 cites W2027114592 @default.
- W2893354345 cites W2029323483 @default.
- W2893354345 cites W2030199647 @default.
- W2893354345 cites W2045413188 @default.
- W2893354345 cites W2056326104 @default.
- W2893354345 cites W2060870400 @default.
- W2893354345 cites W2080518844 @default.
- W2893354345 cites W2082959814 @default.
- W2893354345 cites W2089071484 @default.
- W2893354345 cites W2096283457 @default.
- W2893354345 cites W2105178859 @default.
- W2893354345 cites W2105498840 @default.
- W2893354345 cites W2106714771 @default.
- W2893354345 cites W2111365053 @default.
- W2893354345 cites W2114762637 @default.
- W2893354345 cites W2119274218 @default.
- W2893354345 cites W2133154503 @default.
- W2893354345 cites W2136791645 @default.
- W2893354345 cites W2140684853 @default.
- W2893354345 cites W2141393790 @default.
- W2893354345 cites W2146292887 @default.
- W2893354345 cites W2150014036 @default.
- W2893354345 cites W2157425241 @default.
- W2893354345 cites W2163857222 @default.
- W2893354345 cites W2168534340 @default.
- W2893354345 cites W2170079272 @default.
- W2893354345 cites W2290578664 @default.
- W2893354345 cites W2318605753 @default.
- W2893354345 cites W2416365238 @default.
- W2893354345 cites W2589558051 @default.
- W2893354345 cites W4239989216 @default.
- W2893354345 cites W4244087642 @default.
- W2893354345 doi "https://doi.org/10.1093/jnci/djy151" @default.
- W2893354345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30265336" @default.
- W2893354345 hasPublicationYear "2018" @default.
- W2893354345 type Work @default.
- W2893354345 sameAs 2893354345 @default.
- W2893354345 citedByCount "7" @default.
- W2893354345 countsByYear W28933543452019 @default.
- W2893354345 countsByYear W28933543452020 @default.
- W2893354345 countsByYear W28933543452021 @default.
- W2893354345 countsByYear W28933543452022 @default.
- W2893354345 countsByYear W28933543452023 @default.
- W2893354345 crossrefType "journal-article" @default.
- W2893354345 hasAuthorship W2893354345A5001681907 @default.
- W2893354345 hasAuthorship W2893354345A5024020131 @default.
- W2893354345 hasAuthorship W2893354345A5026587236 @default.
- W2893354345 hasAuthorship W2893354345A5026689196 @default.
- W2893354345 hasAuthorship W2893354345A5033320671 @default.
- W2893354345 hasAuthorship W2893354345A5034859314 @default.
- W2893354345 hasAuthorship W2893354345A5037860926 @default.
- W2893354345 hasAuthorship W2893354345A5061910936 @default.
- W2893354345 hasAuthorship W2893354345A5068859596 @default.
- W2893354345 hasAuthorship W2893354345A5068972361 @default.
- W2893354345 hasAuthorship W2893354345A5073578496 @default.
- W2893354345 hasAuthorship W2893354345A5074604844 @default.
- W2893354345 hasAuthorship W2893354345A5075938435 @default.
- W2893354345 hasAuthorship W2893354345A5090134634 @default.
- W2893354345 hasConcept C121608353 @default.
- W2893354345 hasConcept C126322002 @default.
- W2893354345 hasConcept C143998085 @default.
- W2893354345 hasConcept C2775930923 @default.
- W2893354345 hasConcept C2777329042 @default.